Search
Dalfopristin
go.drugbank.com/drugs/DB01764ApprovedDalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Ferric sulfate
go.drugbank.com/drugs/DB11171ApprovedIt is produced by the reaction of sulfuric acid and an oxidizing agent. … [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003]
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has also been granted orphan drug status by the FDA [L2644].
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15683ApprovedInvestigationalNarsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalBy inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].